Dr. Judith Aberg, MD

• Infectious Disease Medicine

• Internal Medicine

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Washington University School Of Medicine

  Fellowship Hospital, 1996

• Cleveland Clinic Foundation

  Residency Hospital, 1994

• Penn State University College Of Medicine

  Medical School, 1990

• Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers, 2019-03-04

• Soluble Levels of Receptor for Advanced Glycation Endproducts (RAGE) and Progression of Atherosclerosis in Individuals Infected with Human Immunodeficiency Virus: ACTG NWCS 332, 2016-10-01

• Gonorrhea and Chlamydia Case Detection Increased When Testing Increased in a Multisite US HIV Cohort, 2004-2014, 2017-12-01

• Prevalence of and Factors Associated with Prediabetes and Diabetes among HIV-infected Adults in Cameroon, 2016-04-06

• Informative Censoring-A Cause of Bias in Estimating COVID-19 Mortality Using Hospital Data, 2023-01-11

• Lack of Pharmacokinetic Interactions Between Pitavastatin and Efavirenz or Darunavir/Ritonavir, 2014-12-01

• Chronic High Risk Prescription Opioid Use Among Persons With HIV Opioid Prescriptions Among Persons with HIV, 2021-05-18

• Effect of host factors and COVID-19 infection on the humoral immune repertoire in treated HIV, 2023-03-08

• Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial, 2023-01-01

• Soluble levels of receptor for advanced glycation endproducts and dysfunctional high-density lipoprotein in persons infected with human immunodeficiency virus ACTG NWCS332, 2018-06-01

• Pro-inflammatory and pro-resolving lipid mediators of inflammation in HIV: effect of aspirin intervention, 2023-02-13

• Comparing longitudinal CD4 responses to cART among non-perinatally HIV-infected youth versus adults: Results from the HIVRN Cohort, 2017-02-09

• Asymptomatic SARS-CoV-2 Infection is Common among ART-treated People with HIV, 2022-08-01

• High Accuracy of Common HIV-Related Oral Disease Diagnoses by Non-Oral Health Specialists in the AIDS Clinical Trial Group, 2015-07-06

• Rationale and Design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) RCT# NCT02344290, 2019-03-04

• Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)-report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS Clinical Trials Group, 2023-02-13

• Oral shedding of Herpesviruses in HIV+ patients with varying degrees of immune status, 2017-09-24

• Toward Safer Opioid Prescribing in HIV care (TOWER): a mixed-methods, cluster-randomized trial, 2022-05-16

• Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative, 2023-03-09

• Design Aspects of a Case-Control Clinical Investigation of the Effect of HIV on Oral and Gastrointestinal Soluble Innate Factors and Microbes, 2014-11-19

• Combined estimation of disease progression and retention on antiretroviral therapy among treated individuals with HIV in the USA: a modelling study, 2019-07-11

• Assessing Antiretroviral Use During Gaps in HIV Primary Care using Multisite Medicaid Claims and Clinical Data, 2017-09-01

• Convalescent Plasma for the Treatment of Severe COVID-19 Infection in Cancer Patients, 2020-09-17

• An inflammatory cytokine signature predicts COVID-19 severity and survival, 2020-08-24

• Successful recruitment of a multi-site international randomized placebo-controlled trial in people with HIV with attention to diversity of race and ethnicity: Critical role of central coordination, 2020-03-11

• Safety, Tolerability, and Pharmacokinetics of Anti-SARS-CoV-2 Immunoglobulin Intravenous (Human) Investigational Product (COVID-HIGIV) in Healthy Adults: a Randomized, Controlled, Double-Blinded, Phase 1 Study, 2023-02-28